权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Precise Minimally InvasiveTreatment of VT Using Non-invasive Mapping.

使用无创标测对 VT 进行精确的微创治疗。

基本信息

批准号：
9348049
负责人：
Dwight Meglan
金额：
$ 54.79万
依托单位：
HEARTLANDER SURGICAL, INC.
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-15 至 2019-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9348049
关键词：
Ablation Adoption Adverse effects Affect Algorithms Animals Anti-Arrhythmia Agents Area Arrhythmia Blood Vessels Cardiac Cessation of life Chronic Clinic Complex Distress Doppler Ultrasound Electrodes Eligibility Determination Failure Family suidae Film Funding Heart Hour Imagery Implantable Defibrillators Lesion Life Maps Methodology Modeling Morphology Myocardial Myocardial Infarction Myocardium Navigation System Needles Operative Surgical Procedures Pain Pathway interactions Patient-Focused Outcomes Patients Pattern Pericardial body location Pharmaceutical Preparations Phase Physiological Population Process Public Health Radiofrequency Interstitial Ablation Recurrence Risk Safety Saline Shock Signal Transduction Site Small Business Innovation Research Grant System Techniques Technology Testing Therapeutic Thinness Tissues Ultrasonography United States United States National Institutes of Health Ventricular Tachycardia Walkers Work base commercialization computer infrastructure cost design experimental study flexibility hemodynamics implantation improved in vivo innovation innovative technologies miniaturize minimally invasive novel reduce symptoms sensor sudden cardiac death tool

项目摘要

Project Summary Ventricular Tachycardia (VT) is a major public health problem associated with the majority of the 300,000 cases of sudden cardiac death in the United States each year. The best current therapy for VT involves drugs to reduce VT episodes plus implantation of a cardiac defibrilator (ICD) that prolongs life by terminating episodes of VT. Permanent cessation of VT can be achieved by ablation of the origin site(s) and exit pathway(s) of the arrhythmia. Despite the advantages of this technique, its adoption has been limited because it is currently appropriate only for the few patients with hemodynamically stable VT. This project will create a disruptive, less expensive, more effective, and safer system for minimally invasive identification and ablation of critical VT sites. It will combine the HeartLander (HL) epicardial walker with a non-invasive mapping technology and a flexible, needle-based, radio frequency ablation technique. In prior work we have demonstrated that these technologies can be integrated into a unified system and have also eliminated major technical risks of the technologies. In this Fast Track SBIR application, we propose to complete the integration of the technologies and then verify the efficacy of the system in a Yorkshire swine pig model of VT. Upon successful completion, we will be ready to advance to the clinic a simpler, safer, more reliable and less expensive approach to effectively treating the 500,000 annual cases of ventricular tachycardia. We will also have built the hardware and computation infrastructure to support additional mapping methodologies that will enable the treatment of complex multi-focal arrhythmias.

项目总结